Distractibility in ADHD associated with reduced ability to modulate alpha band oscillations in attentional tasks

Completed

Conditions: ADHD
attention deficit and hyperactivity disorder
10009841

Registration Number: NL-OMON43451

Lead Sponsor: Radboud Universiteit Nijmegen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 80

Inclusion Criteria

For both groups inclusion criteria will be: (1) Age between 8 and 12 years. (2) Enrolled in primary (not secondary) school. (3) Estimated IQ above 80.
For the ADHD-group an additional inclusion criterion will be: (1) a clinical diagnosis of ADHD according to the criteria of the DSM-V (see *Study procedures* for detailed description). (2) Scored in the clinical range on the ADHD DSM-IV rating scale, completed by parents. (3) Pharmacological treatment with Methylphenidate (either long- or short-acting formulations), which started at least 3 months before the inclusion in the study.

Exclusion Criteria

For both groups exclusion criteria will be: (1) (Co-morbid) psychiatric disorder (major depression, bipolar disorder, psychotic disorder, chronically motor tic disorder or Gilles de la Tourette, Conduct disorder, autism spectrum disorder, eating disorder, anxiety disorder). (2) Neurological disorders (e.g. epilepsy) currently or in the past. (3) Cardiovascular disease currently or in the past. (4) Serious motor or perceptual handicap. (5) Standard MRI Exclusion criteria according to DCCN regulations (see attached pdf in cmo application section: K6: *MR algemene informatie*).

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Alpha Modulation Index (AMI) and Alpha Lateralization Index (ALI) will be<br /><br>computed and compared between ADHD and control groups and within ADHD between<br /><br>on- and off-medication conditions; Furthermore the volume of the Superior<br /><br>Longitudinal fascicles will be estimated by means of DTI analysis and the<br /><br>volume of the striatum by means of voxel based morphometry analysis of MRI data.<br /><br>Primary analysis will then focus on:<br /><br>- Difference in ALI and AMI between patients and controls and within<br /><br>patients, between conditions MPH and placebo.<br /><br>- Difference in SLF volume between patients and control.<br /><br>- Correlation between ALI and SLF lateralization.<br /><br>- Difference in striatal brain volume between patients and controls.<br /><br>- Correlation between striatal volume and Alpha Modulation Index.</p><br>

Secondary Outcome Measures